Olanzapine: A basic science update

British Journal of Psychiatry

Volumn 174, Issue FEB. SUPPL. 37, 1999, Pages 36-40

  Bymaster, Franklin ^a   Perry, Kenneth W ^a   Nelson, David L ^a   Wong, David T ^a   Rasmussen, Kurt ^a   Moore, Nick A ^a   Calligaro, David O ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; OLANZAPINE; SEROTONIN 2A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR; DRUG DERIVATIVE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; PIRENZEPINE; SEROTONIN RECEPTOR;

DOPAMINE BRAIN LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; ANIMAL; DRUG EFFECT; GENE EXPRESSION; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; GENE EXPRESSION; HUMANS; PIRENZEPINE; RECEPTORS, DOPAMINE; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0032989684     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000293653     Document Type: Review

References (18)

1. Bymaster, F. P., Calligaro, D. O., Marsh, R. D., et al (1996a) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
2. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology, 124, 87-94.
3. _, Nelson, D. L., DeLapp, N. W., et al (1996c) The atypical antipsychotic olanzapine is an antagonist at dopamine, serotonin and muscarinic receptor subtypes. Schizophrenia Research, 18, 139.
4. _, Li, X.-M., Carter, P. A., et al (1997a) Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo. Schizophrenia Research, 24, 74.
5. _, Rasmussen, K., Calligaro, D. O., et al (1997b) In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Journal of Clinical Psychiatry, 58 (suppl. 10), 28-36.
6. Calligaro, D., Fairhurst, J., Hotten, T. M., et al (1996) The synthesis and biological activity of some known metabolites of the atypical antipsychotic agent olanzapine (LY170053). Biorganic Medicinal Chemistry Letters, 7, 25-30.
7. Deutch, A.Y. (1992) The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. Journal of Neural Transmission, 36 (suppl.), 61-89.
8. Fuller, R.W. & Snoddy, H. D. (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Research Communications in Chemical Pathology and Pharmacology, 77, 87-93.
9. Li, X.-M., Perry, K.W., Wong, D.T., et al (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology, 136, 153-161.
10. Lucaites, V. L., Bymaster, F. P., Wainscott, D. B., et al (1995) Olanzapine exhibits similar activities to clozapine at cloned human serotonin 2A, 2B, 2C and muscarinic receptors. Society of Neuroscience Abstracts, 21, 1125.
11. Robertson, G. S. & Fibiger, H. C. (1991) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience, 46, 315-328.
12. _ & _ (1996) Effects of Olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacalogy, 14, 105-110.
13. 7 receptors. Journal of Pharmacology and Experimental Therapeutics, 268, 1403-1410.
14. 3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn-Schmiedebergs Archives of Pharmacology, 353, 290-294.
15. Schotte, A., Janssen, P. F. M., Gommeren, W., et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology, 124, 57-73.
16. Skarsfeldt, T. (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. European Journal of Pharmacology, 281, 289-294.
17. Stockton, M. E. & Rasmussen, K. (1996) Electrophysiological effects of Olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmocology, 14, 97-104.
18. Zeng, P. X., Le, F. & Richelson, E. (1997) Muscarinic M4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology, 321, 349-354.